Trifluoromescaline (TFM), also known as 4-(trifluoromethoxy)-3,5-dimethoxyphenethylamine, is a derivative of the phenethylamine psychedelic mescaline, which has a 4-trifluoromethoxy group replacing the 4-methoxy group of mescaline. It was found to be one of the most potent compounds in the scaline series, with a reported dose of 15 to 40 mg (and 60 mg being described as a "strong overdose"), and a slow onset of action and long duration of effects, lasting 14 to 24 hours. The drug showed about 34-fold higher affinity and 36-fold greater activational potency at the serotonin 5-HT2A receptor compared to mescaline in vitro. In addition, it appears to be much more lipophilic than mescaline (predicted log P = 1.9 vs. 0.7, respectively). Analogues of trifluoromescaline include the fluorinated scalines difluoromescaline, metadifluoromescaline, fluoroescaline, difluoroescaline, trifluoroescaline, fluoroproscaline, and trifluoroproscaline, among others. Some other analogues include the fluorinated phenethylamines 2C-TFM, DOTFM, 2C-TFE, DOTFE, 2C-T-28 (2C-T-FP), 2C-T-36 (2C-T-TFM), and 3C-DFE, among others. TFM was first described in the scientific literature by Daniel Trachsel by 2012. Many other related compounds have also been described by Trachsel and colleagues. It is not a controlled substance in Canada as of 2025.
See also Scaline
References
External links Trifluoromescaline - Isomer Design Hallucinogens You Probably Haven't Heard of: Halogenated Mescaline Analogues - Nervewing - Blogger


